Autogene Cevumeran plus Atezolizumab and mFolfirinox vs mFolfirinox alone (Pancreatic Cancer) - Clinical Trial
Email to Participate
jennifer.gallagher@duke.edu
What is the Purpose of this Study?
We are doing this study to compare 2 different regimens for treating pancreatic cancer after surgery. We what find out how well patients do after they get a combination of the drugs cevumeran, atezolizumab, and mFOLFIRINOX compared to just getting mFOLFIRINOX alone. Cevumeran is an experimental drug that is made from your own cells that are obtained from blood and tissue samples. It is designed to activate your immune system against cancer cells in your body.
What is the Condition Being Studied?
Pancreatic Cancer
Who Can Participate in the Study?
Adults ages 18+ who:
- Are diagnosed with pancreatic cancer
- Are able to have surgery to remove the cancer
For more information about who can join this study, contact the study team at jennifer.gallagher@duke.edu.
Age Group
Adults
What is Involved?
If you choose to join this study, you will get a random assignment (like a coin flip) to either:
- Get the combination of autogene cevumeran plus atezolizumab and mFOLFIRINOX; OR
- Get mFOLFIRINOX alone
Study Details
Full Title
A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF ADJUVANT AUTOGENE CEVUMERAN PLUS ATEZOLIZUMAB AND mFOLFIRINOX VERSUS mFOLFIRINOX ALONE IN PATIENTS WITH RESECTED PANCREATIC DUCTAL ADENOCARCINOMA
Principal Investigator
Daniel P. Nussbaum, MD
Gastrointestinal Surgeon
Protocol Number
IRB:
PRO00113749
NCT:
NCT05968326
Phase
Phase
II
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate